CURRICULUM VITA

侯自銓 博士 (Tzyh-Chyuan Hour, Ph. D.)

Born: October, 1965, Tainan

Sex: Male

Marital Status: Married, 1996.

Lab: (07) 3121101 ext 2242-16

e-mail: cliff@cc.kmu.edu.tw

web: http://hourlab.dlearn.kmu.edu.tw/

Education and Training:

1986/10-1990/7: (B.S.) Department of Biology, TungHai University, Taichung, Taiwan

1992/9-1994/7: (M.S) Institute of Biochemistry, National Taiwan University, Taipei, Taiwan

1994/9-1998/12: (Ph.D.) Institute of Biochemistry, National Taiwan University, Taipei, Taiwan

Academic and Professional Appointments:

1999/2-1999/7: Post Dr. Research Fellow in Institute of Pharmacology, College of Medicine, National Taiwan University, Taiwan.

2000/2-2000/6: Visiting Lecturer in Department of Food Science, Nutrition and Nutraceutical Biotechnology, Shih Chien University, Taipei, Taiwan.

1999/8-2001/7: Post Dr. Research Fellow in Departments of Urology and Oncology, National Taiwan University Hospital, Taiwan.

2001/8-2008/8: Assistant Professor, institute of biochemistry, Kaohsiung Medical University, Kaohsiung, Taiwan

2005/9-2006/1: Visiting Lecturer in Department of Pharmacy, Chia Nan

University of Pharmacy and Science, Tainan, Taiwan.

2006/2-2008/7: Visiting Lecturer in Department of Sea-Food Science, National Kaohsiung Marine University, Kaohsiung, Taiwan.

2008/8-2009/7: Assistant Research Fellow in Center of Excellence for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

2009/1-2009/2: Visiting Scientist in BioResource Center RIKEN, Tsukuba, Japan.

Board of Academic Societies

2005/8-2007/7: Director in Technician Training Division of Proteomic Center, Kaohsiung Medical University, Kaohsiung, Taiwan.

2008~present: Member in committee for designed and organized of courses in Institute of Biochemistry, Kaohsiung Medical University, Kaohsiung, Taiwan.

2008~present: Lecturer of General Affair in Institute of Biochemistry, Kaohsiung Medical University, Kaohsiung, Taiwan.

Current Position:

2008/8-present: Associate Professor, Institute of Biochemistry, Kaohsiung Medical University, Kaohsiung, Taiwan.

Specialty:

Molecular Carcinogenesis, Tumor Biology, Urological Oncology, Biochemistry and Cell Biology

Research Interest:

To search the biomarkers and explore the chemoresistant mechanisms in urological cancers for the clinical application

Awards

1. Award of excellent poster in Proceedings of the 5th annual conference of Taiwan Cancer Association (2000).
2. Award for excellent teaching performance, Kaohsiung Medical University (2005).
3. Award for excellent teaching performance, Kaohsiung Medical University (2006).
4. Award for excellent teaching performance, Kaohsiung Medical University (2007).

5. Award for excellent teaching performance, Kaohsiung Medical University (2008).
6. Award for excellent teaching performance, Kaohsiung Medical University (2009).
7. Award of excellent poster in Proceedings of the 16th annual conference of Taiwan Cancer Association (2011).
8. Confucius award for excellence in teaching, Kaohsiung Medical University (2011).

Membership of Academic Societies

2001/8 -present: Taiwan Oncology Society

Editorship or Board Membership of Biomedical Journals

2010/11-present: ISRN Oncology Editorial Board

2010/12-present: World Journal of Pharmacology

Reviewer for Scientific Journals or Projects

2006: Project of CANCER RESEARCH UK (UK)

2006: FEBS Letters (Germany)

2007-2009: Journal of Cancer Molecules (Taiwan)

2009: Cancer Chemotherapy and Pharmacology (UK)

2009: Journal of Agricultural and Food Chemistry (USA)

2011: Cancer Research (USA)

2011: ISRN Oncology (USA)

Publications:

1. **Hour, T. C.**, Lee, C. C. and Lin, J. K. (1995) A new mutagenicity assay method for frameshift mutagens based on deleting or inserting a guanosine nucleoside in the β-lactamase gene. **Mutagenesis** 10, 433-438. (SCI, Times Cited: **4**)

2. **Hour, T. C.**, Chen, L. and Lin, J. K. (1998) Comparative investigation on the mutagenicities of organophosphate, phthalimide, pyrethroid and carbamate insecticides by the Ames test and lactam tests. **Mutagenesis** 13, 157-166. (SCI, Times Cited: **26**)

3. **Hour, T. C.**, Liang, Y. C., Chu I. S. and Lin J. K. (1999) Inhibition of eleven mutagens by various tea extracts, (-)epigallocatechin-3-gallate, gallic acid

and caffeine. **Food and Chemical Toxicology**. 37(6) 569-79 (SCI, Times Cited: **46**)

4. **Hour, T. C.**, Lin-Siau, S. Y. and Lin, J. K. (1999) Suppression of *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine- and *S*-nitrosoglutathione-induced apoptosis by Bcl-2 through inhibiting glutathione-*S*-transferase π in NIH3T3 cells. **Toxicology Letter** 110, 191-202. (SCI, Times Cited: **15**)

5. **Hour, T. C.**, Chen, L. and Lin, J. K. (2000) Suppression of the activity of transcription of factor NF-κB by Bcl-2 protein in NIH3T3 cells: Implication of a novel NF-κB p50-Bcl-2 complex for the anti-apoptotic function of Bcl-2. **European Journal of Cell Biology** 79, 121-129 (NSC-87-2621- B002-008-Z). (SCI, Times Cited: **17**)

6. **Hour, T. C.**, Chen, J, Huang, C. Y., Guan, C. Y., Lu, S. H., Hsieh, C. Y. and Pu, S.Y. (2000) Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines. **Anticancer Res.**, 20, 3221-3226. (SCI, Times Cited: **20**)

7. Pu, Y. S., Cheng, J., Huang, C. Y., Guan, J. Y., Lu, S. H. and **Hour, T. C.** (2001) Cross resistance between and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells. **J. Urology** 165, 2082-2085. (SCI, Times Cited: **8**)

8. **Hour, T. C.**, Huang, C. Y., Guan, J. Y., Lu, S. H., Cheng, J. and Pu, Y. S. (2002) Curcumin enhances doxorubicin cytotoxicity in prostate cancer cells by suppression of NF-κB activation and induction of $p21^{WAF1/CIP1}$ and C/EBPβ expressions. **Prostate**. 15;51(3):211-8. (SCI, Times Cited: **46**)

9. Pu Y. S., **Hour, T. C.**, Chen, J, Huang, C. Y., Guan, J. Y. and Lu, S. H. (2002) Arsenic trioxide as a novel anticancer agent against human transitional carcinoma--characterizing its apoptotic pathway. **Anticancer Drugs** 13(3):293-300. (SCI, Times Cited:**35**)

10. Pu, Y. S., **Hour, T. C.**, Chen, J., Huang, C. Y., Guan, J. Y. and Lu, S. H. (2002) Cytotoxicity of arsenic trioxide to transitional carcinoma cells. **Urology** 60(2):346-350. (SCI, Times Cited: **15**)

11. Pu Y. S., **Hour, T. C.**, Chuang S. E., Cheng A. L., Lai M. K. and Kuo M. L. (2004) Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. **Prostate** 60, 120-129. (SCI, Times Cited: **20**)

12. **Hour, T. C.**, Huang, C. Y., Lin C. C., Cheng, J., Guan, J. Y., Lee, J. M. and Pu, Y. S. (2004) Characterization of molecular events in a series of bladder urothelial carcinoma cells with progressive resistance to arsenic trioxide. **Anticancer Drugs** 15, 779-785. (SCI, Times Cited: **8**)

13. Yang, S. H., Lu, M. C., Chien, C. M., Tsai, C. H., Lu, Y. J., **Hour, T. C.** and Lin, S. R. (2005) Induction of apoptosis in human leukemia K562 cells

by cardiotoxin III. **Life Science** 76, 2513-2522. (SCI, Times Cited: **21**)

14. Liao, Y. F., Hung, Y. C., Chang, W. H., Tsay, G. J., **Hour, T. C.,** Hung, H. C., and Liu, G. Y. (2005) The PKC delta inhibitor, rottlerin, induces apoptosis of haematopoietic cell lines through mitochondrial membrane depolarization and caspases' cascade. **Life Science** 77(6):707-719 (SCI, Times Cited: **30**).

15. Huang, C. C., Hsu, P. C., Hung, Y. C., Liao, Y. F., Liu C. C., **Hour, T. C.,** Kao, M. C., Tsay, G. J., Hung, H. C. and Liu, G. Y. (2005) Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production. **Apoptosis** 10(4):895-907. (SCI, Times Cited: **16**)

16. Ramanathan, B., Chen, C. H., Jan, K .Y., **Hour, T. C.**, Yu, H. J., and Pu, Y. S. (2005) Resistance to paclitaxel is proportional to total cellular antioxidation capacity. **Cancer Res** 65(18):8455-8460. (SCI, Times Cited: **44**)

17. Hsu, P. C., **Hour, T. C.**, Liao, Y. F., Hung, Y. C., Liu, C. C., Chang, W. H., Kao, M. C., Tsay, G. J., Hung, H. C. and Liu, G. Y. (2006) Increasing Ornithine decarboxylase activity is another way of prolactin preventing methotrexate-induced apoptosis: crosstalk between ODC and BCL-2. **Apoptosis** 11(3):389-399. (SCI, Times Cited: **7**)

18. Pu, Y. S., Hsieh, M. W., Wang, C. W., Chin, H. C., Huang, C. Y., Lin, C. C., Guan, J. Y., Lin, S. R. and **Hour, T. C.*** (2006) Epidermal growth factor Receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. **Biochem Pharma** 71(6):751-760. (SCI, Times Cited: **17**)

19. **Hour, T. C,** Huang S. W., Lin, C. C., Huang, C. Y., Chen, Jun., Chiu, A. W., Chen, C. J. and Pu, Y. S. (2006) Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancer. **Anticancer Res** 26(1A):375-378. (SCI, Times Cited: **3**)

20. Huang, Y. T., Huang, Y. H., **Hour, T. C.,** Pan, B. S., Liu, Y. C. and Pan, M. H. (2006) Apoptosis-inducing active components from *Corbicula fluminea* through activation of caspase-2 and production of reactive oxygen species in human leukemia HL-60 cells. **Food Chem Toxicol** 44(8):1261-1272. (SCI, Times Cited: **7**)

21. Liu, G. Y., Liao, Y. F., Hsu, P. C., Chang, W. H., Hsieh, M. C., Lin, C. Y., **Hour, T.C.,** Kao, M. C., Tsay, G. J. and Hung, H. C. (2006) Antizyme, a natural ornithine decarboxylase inhibitor, induces apoptosis of aematopoietic cells through mitochondrial membrane depolarization and caspases' cascade. **Apoptosis** 11(10):1773-1788. (SCI, Times Cited: **6**)

22. Lin, C. C., Hsu, C. H., **Hour, T. C.,** Cheng, A. L., Huang, C. Y., Huang, K. H., Chen, J. and Pu, Y. S. (2007) Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in

vitro combined effects and a phase II trial. **Uro Oncol-Semin** 25: 207-213. (SCI, Times Cited: **1**)

23. Liu, C. H., Huang, J. D., Huang, S. W., **Hour, T. C.,** Huang, Y. K., Hsueh Y. M., Chiou, H. Y., Lee, T. C., Jan, K. Y., Chen, C. J. and Pu, Y. S. (2008) Androgen receptor gene polymorphism may affect the risk of urothelial carcinoma. **J Biomed Sci** 15(2):261-269. (SCI, Times Cited: **1**)

24. Liao, Y. F., Hung, H. C., Hsu, P. C, Kao, M. C., **Hour, T. C.,** Tsay, G. J. and Liu, G. Y. (2008) Ornithine decarboxylase interferes with macrophage-like differentiation and matrix metalloproteinase-9 expression by tumor necrosis factor alpha via NF-κB. **Leukemia Research** 32(7):1124-40**.** (SCI, Times Cited: **2**)

25. Liao, Y. F., Hung, H. C., **Hour, T. C.,** Hsu, P. C., Kao, M. C., Tsay, G. J. and Liu G. Y. (2008) Curcumin induces apoptosis through ornithine decarboxylase-dependent pathway in human promyelocytic leukemia HL-60 cells. **Life Science** 82(7-8):367-375. (SCI, Times Cited: **10**)

26. Pu, Y. S., Wang, C. W., Liu, G. Y., Kuo, Y. Z., Huang, C. Y., Kang, W. Y., Shun, C. T., Lin, C. C., Wu, W. J., and **Hour, T. C.*** (2008) Down-regulated Expression of RhoA in human conventional renal cell carcinoma. **Anticancer Res** 28:2039-2044.

27. **Hour, T. C.,** Kuo, Y. Z., Liu, G. Y., Kang, W. I., Huang, C. Y., Tsai, Y. C, Wu, W. J., Huang, S. P. and Pu, Y. S. (2009) Down-regulation of ABCD1 in human renal cell carcinoma. **Int J Biol Markers** 24 (3): 171-178

28. Pu, Y. S., Huang C. Y., Kuo, Y. Z., Kang, W. Y., Liu, G. Y., Huang, A. M., Yu, H. J., Lai, M. K, Huang, S. P., Wu, W. J., Chiou, S. J. and **Hour, T. C.*** (2009) Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma. **Journal Biomed Science** 12;16(1):82-92. (SCI, Times Cited: **1**)

29. Lin, K. W., Huang, A. M., Tu, H. Y., Weng J. R., **Hour, T. C.,** Wei, B. L., Yang, S. C., Wang, J. P., Pu, Y. S. and Lin, C. N. (2009) Phloroglucinols Inhibit Chemical Mediators and Xanthine Oxidase, and Protect Cisplatin-Induced Cell Death by Reducing Reactive Oxygen Species in Normal Human Urothelial and Bladder Cancer Cells. **J. Agric. Food Chem.** 14;57(19):8782-8787.

30. Tu, H. Y., Huang, A. M., Wei, B. L., Gan, K. H., **Hour, T. C.,** Yang, S. C., Pu, Y. S. and Lin, C. N. (2009) Ursolic acid derivatives induce cell cycle arrest and apoptosis in NTUB1 cells associated with reactive oxygen species. **Bioorg. & Med. Chem.** 15;17(20):7265-7274. (SCI, Times Cited: **1**)

31. Chen, H. L., Lin, K. W., Huang, A. M., Tu, H. Y., Wei, B. L., **Hour, T. C.,** Yen, M. H., Pu, Y. S. and Lin, C. N. **(**2010**)** Terpenoids induce cell cycle arrest and apoptosis from the stems of Celastrus kusanoi associated with reactive oxygen species. **J Agric Food Chem.** 58(6):3808-12.

32. Tu, H. Y., Huang, A. M., **Hour, T. C.,** Yang, S. C., Pu, Y. S. and Lin, C. N. (2010) Synthesis and biological evaluation of 2',5'-dimethoxychalcone derivatives as microtubule-targeted anticancer agents. **Bioorg Med Chem.** 18(6):2089-98.

33. Ping, S. Y.,* **Hour, T. C.,*** Lin S. R. and Yu D. S. (2010) Taxol synergizes with antioxidants in inhibiting hormal refractory prostate cancer cell growth. **Uro Oncol-Semin**. 28:170-179 (*****: **co-first authors**). (SCI, Times Cited: **1**)

34. **Hour, T. C.,** Lai, Y. L., Kuan, C. I., Chou, C. K., Wang, J. M., Tu, H. Y., Lin, C. S., Wu, W. J., Pu, Y. S., Sterneck, E. and Huang, A. M. (2010) CEBPD induces SOD1 expression and cisplatin resistance in human urothelial carcinoma cells. **Biochem Pharma** 80:325-334

35. Huang, C. Y., Chen, Jeff Y. F., Wu, J. E., Pu, Y. S., Liu, G. Y., Pan M. H., Huang Y. T., Huang, A. M., Hwang C. C., Chung S. J. and **Hour T. C.*** (2010) Ling-Zhi polysaccharides potentiates cytotoxic effects of anti-cancer drugs against drug-resistant urothelial carcinoma cells. **J. Agric. Food Chem**. 58: 8798-8805.

36. Chiu, C. C., Chen, B. H., Hour, T. C., Chiang, W. F., Wu, Y. J., Chen, C. Y., Chen, H. R., Chan, P. T., Liu, S. Y. and Chen, Jeff Y. F. (2010) Betel quid extract promotes oral cancer cell migration by activatinga muscarinic M4 receptor-mediated signaling cascade involving SFKs and ERK1/2. **Biochem. Biophys. Res. Commun.** 13;399(1):60-65.

37. Lin, C.N., Huang, A. M., Lin, K. W., **Hour, T. C.**, Ko, H. H., Yang, S. C., and Pu, Y. S. (2010) Xanthine oxidase inhibitory terpenoids of Amentotaxus formosana protect cisplatin-induced cell death by reducing reactive oxygen species (ROS) in normal human urothelial and bladder cancer cells. **Phytochemistry** 71(17-18):2140-6.

38. Lin, K. W., Huang, A. M., Tu, H. Y., Lee, L. Y., Wu, C. C., **Hour, T. C.,** Yang, S. C., Pu, Y. S. and Lin C. N. (2010) Xanthine oxidase inhibitory triterpenoid and phloroglucinol from guttiferaceous plants inhibit growth and induced apoptosis in human NTUB1 cells through a ROS-dependent mechanism. **J. Agric. Food Chem**. 59(1):407-14.

39. Cheng, J. H, Huang, A. M., **Hour TC,** Yang, S. C., Pu, Y. S. and Lin, C. N. (2011) Antioxidant xanthone derivatives induce cell cycle arrest and apoptosis and enhance cell death induced by cisplatin in NTUB1 cells associated with ROS. **Eur J Med Chem.** 46(4):1222-31.

40. Wang, M. F., Liao, Y. F., Hung, Y. C., Lin, C. L., **Hour, T. C.,** Lue K. H., Hung, H. C. and Liu, G. Y. (2011) Hydroxydibenzoylmethane induces apoptosis through repressing ornithine decarboxylase in human promyelocytic leukemia HL-60 cells. **Exp Mol Med.** 43(4):189-96.

41. Huang, A. M., Kao, Y. T., Toh, S., Lin, P. Y., Chou, C. H., Hu, H. T., Lu, C. Y., Liou, J. Y., Chao, S.Y., **Hour, T.C.** and Pu YS. (2011) UBE2M-mediated p27(Kip1) degradation in gemcitabine cytotoxicity. **Biochem Pharma.** 82(1):35-42.

42. Chiang, W. F., Ho, H. C., Chang, H. Y., Chiu, C. C., Chen, Y. L., **Hour, T. C.,** Chuang, S. J., Wu, Y. J., Chen, H. R., Chen, J. H., Shyun-Yeu Liu, S. Y. and Chen, Y. F. Jeff (2011) Expression of Rho GDP-dissociation inhibitor alpha is essential for oral cancer cell migration and predicts poor survival of oral squamous cell carcinoma. **Oral Oncology** 47(6):452-8.

43. Lin, K. W., Huang, A. M., **Hour, T. C.**, Yang, S. C., Pu, Y. S. and Lin, C. N. (2011) 18β-Glycyrrhetinic acid derivatives induced mitochondrial-mediated apoptosis through reactive oxygen species-mediated p53 activation in NTUB1 cells. **Bioorg Med Chem**.15;19(14):4274-85.

44. Cheung, C. H., Lin, W. H., Hsu, J. T., **Hour, T. C.,** Yeh, T. K., Ko, S., Lien, T. W., Coumar, M. S., Liu, J. F., Lai, W. Y., Shiao, H. Y., Lee, T. R., Hsieh, H. P. and Chang J. Y. (2011) BPR1K653, a Novel Aurora Kinase Inhibitor, Exhibits Potent Anti-Proliferative Activity in MDR1 (P-gp170)-Mediated Multidrug-Resistant Cancer Cells. **PLoS One.** 6(8):e23485.

45. Huang, C. N., Huang, S. P., Pao, J. B., **Hour T. C.,** Chang, T. Y., Lan, Y. H., Lu, T. L., Lee, H. Z., Juang, S. H., Wu, P.P., Huang, C. Y., Hsieh, C. J. and Bao, B. Y. (2011) Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy. **J Intern Med.** (in press)

46. Tu YP, Chuang SJ, Chen SC, Liu YH, Chen CF, **Hour TC.*** (2011) Simvastatin induces the expression of hemeoxygenase-1 against ischemia-reperfusion injury on the testes in rats. **Toxicol Lett.** (in press)

Conferences:

1. Lin, J. K., **Hour, T. C.,** Lee, C. C. and Lin-Shiau, S. Y. (1997) New salmonella tester strains for detecting point and frameshift mutagens. **Proceedings of the 1st International Conference of Asian Society of Toxicology**, p131.

2. **Hour, T. C.**, Guan, J. Y., Lu S. H., Huang, C. Y., Yang, C. H. and Pu, Y. S. (2000) Buthionine sulfoximide may sensitize cells to arsenic trioxide: a novel therapeutic strategy for transitional carcinomas. **Proceedings of the 91th American Association for Cancer Research**, ***Vol. 41***, p178 (#1138).

3. **Hour, T. C.**, Huang, C. Y., Guan, J. Y., Lu S. H., Cheng J and Pu, Y. S. (2000) Curcumin enhances doxorubicin cytotoxicity in prostate cancer cells by suppression of NF-κB activation and induction of $p21^{WAF1/CIP1}$ and C/EBPβ expressions. **Proceedings of the 5th annual conference of Taiwan Cancer Association**.

4. **Hour, T. C.**, Guan, J. Y., Lu, S. H., Huang, C. Y., Yang, C. H. and Pu, Y. S. (2000) Arsenic cytotoxicity to transitional carcinomas cells is through reactive oxygen species-related apoptotic pathways. **Proceedings of the 12th annual conference of the Urological Association of Taiwan,** p24.

5. **Hour, T, C.**, Huang, C. Y., Guan, J. Y., Lu, S. H., Cheng, J. and Pu, Y. S. (2000) Schedule-dependence of combined treatment of BSO and arsenic-optimizing cytotoxic effect to transitional carcinoma cells. **Proceedings of the 12th annual conference of the Urological Association of Taiwan,** p28.

6. **Hour, T. C.** Chen, J., Huang, C. Y., Guan, J. Y., Lu, S. H. and Pu, Y. S. (2001) Characterization of the molecular events in a series of bladder carcinoma cells with progressive arsenic trioxide resistance. **Proceedings of the 92th American Association for Cancer Research**, ***Vol. 42***, p645 (#3470).

7. **Hour, T. C.**, Pu, Y. S., Chen, J., Huang, C. Y., Guan, J. Y., and Lu, S. H. (2001) Characterization of arsenic cytotoxicity to transitional carcinoma cells: emphases on cross-resistance to cisplatin and exploration of apoptotic pathway. **Proceedings of the 5th International Conference of the Asian Clinical Oncology Society and the 6th Taiwan Joint Cancer Conference**, p73 (A-20).

8. Pu, Y. S., **Hour, T. C.**, Huang, C. Y., Guan, J. Y., and Lu, S. H., and Chen, J. (2001) Differential expressions of molecular markers in androgen-dependent and independent prostate cancer cells, **Proceedings of the 13th annual conference of the Urological Association of Taiwan**, p229 (C23).

9. **Hour, T. C.**, Pu, Y. S., Huang, C. Y., Guan, J. Y., and Lu, S. H., and Chen, J. (2001) Molecular Events in a Series of Bladder Carcinoma Cells with Progressive Resistance to Arsenic Trioxide, **Proceedings of the 13th annual conference of the Urological Association of Taiwan**, p124 (A28).

10. **Hour, T. C.** Huang, C. Y., Guan, J. Y., Lu, S. H. Chen, J. and Pu, Y. S. (2002) Differential expressions of molecular markers in androgen-dependent and independent prostate cancer cells, **Proceedings of the 93th American Association for Cancer Research**, ***Vol. 43***, p382 (#1901).

11. Yang, S. H., Chien, C. M., Tsai, C. H., Lu, Y. J., Horng, C. J., **Hour, T. C.** and Lin, S. R. (2003) *In vitro* antitumor activity of cardiotoxins. **The Annual Meeting of Chinese Chemistry Society**. OR-19.

12. **Hour, T. C.**, Huang, S. W., Lin, C. C., Huang, C. Y., Chen, J., Chiu, A. W., Chen, C. J., Pu, Y. S. (2004) Expression of molecular markers in arsenic-related bladder urothelial carcinoma ---distinction from non-arsenic related BUC in Taiwan. **Proceedings of the 95th American Association for Cancer Research**, ***Vol. 45***, p266 (#1164).

13. **Hour, T. C.,** Wang, C. W., Hsieh, M. W., Chin, H. C., Kuo, Y. Z., Huang C. Y., Guan, J. Y. and Pu, Y. S. (2005) Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. **Proceedings of the International Chemical Congress of Pacific Basin Societies,** p231.

14. Huang, A. M., Guan, J. Y., Pu, Y. S. and **Hour, T. C.** (2007) The molecular roles of transcription factor C/EBPdelta in cisplatin-resistant urothelial carcinoma cells. **第 15 屆細胞及分子生物新知研討會**, p266.

15. **Hour, T. C.,** Kuo, Y. Z., Kang, W. Y., Yu, H. J., Huang, S. P., Wu, W. J., Huang, C. H., Chai, C. Y., Pu, Y. S. (2007) Down-regulation of ABCD1 may be involved in tumorigenesis of human renal cell carcinoma. **The 12th Taiwan Joint Cancer Conference and 6th Cross-Strait Academic Conference on Oncology**, p112 (A-I-08).

16. Kuo, Y. Z., **Hour, T. C.,** Kang, W. Y., Liu, G. Y., Huang, A. M., Chen, C. J., Shiu , Y. S., Kuan, C. I., Wu, J. E., Pu, Y. S. (2007) Membranous or cytoplasmic localization of EGFR may be associated with human renal tumorigenesis. **The 12th Taiwan Joint Cancer Conference and 6th Cross-Strait Academic Conference on Oncology**, p113 (A-I-09).

17. Chen, C. J., **Hour, T. C.,** Kuo, Y. Z., Kang, W. Y., Huang, S. P., Wu, W. J., Huang, C. Y., Yu, H. J., Pu, Y. S. (2007) Down-regulation of PKCζ in human renal cell carcinoma. **The 12th Taiwan Joint Cancer Conference and 6th Cross-Strait Academic Conference on Oncology**, p114 (A-I-10).

18. Kuan, C. I., Huang, A. M., **Hour, T. C.,** Liu, G. Y., Wu, J. E., Kuo, Y. Z., Chen, C. J., Shiu , Y. S., Huang, K. H., Pu, Y. S. (2007) Mechanism of cisplatin-resistance in overexpression of C/EBP δ urothelial Carcinoma cells was through inhibition of P53 phosphorylation, Bcl-2 down-regulation and ERK inactivation. **The 12th Taiwan Joint Cancer Conference and 6th Cross-Strait Academic Conference on Oncology**, p118 (A-I-15).

19. **Hour, T. C.,** Kuo, Y. Z., Kang, W. Y., Yu, H. J., Huang, S. P., Wu, W. J., Pu, Y. S. (2007) Down-regulation of ABCD1 may be involved in tumorigenesis of human renal cell carcinoma. **The 32nd FEBS Congress**, **FEBS Journal, vol 274, suppl 1, p177 (C2-112).**

20. Huang, S. P., Liu, C. C., Kang, W. Y., **Hour, T. C.,** Lin, H. C., Wu, W. J., Huang, C. H., Wang, J. S., Yu, C. C., Wu, T. T., Ming-Tsang Wu, M. T., Chang. C. P. (2007) E-cadherin -160 C/A Polymorphism and Prostate Cancer Risk in Taiwan. **Proceedings of the 29th annual conference of**

the Urological Association of Taiwan

21. Huang, S. P., Yu, C. C., Liu, C. C., Huang, C. Y., Wang, J. S. Pu, Y. S., Yu, H. J., Wu, T. T., Huang, C. H., Wu, W. J., Kang, W. Y., **Hour, T. C.,** Ming-Tsang Wu. (2008) Prognostic significance of cyclin D1 A870G polymorphisms on prostate specific antigen recurrence in prostate cancer post-radical prostatetomy. **The 6th Taiwan Surgical Association Conference**.
22. Lai, Y. L., Kuan, C. I., **Hour, T. C.,** Pu, Y. S., Huang, A. M. (2008) The molecular roles of transcription factor CEBPD-mediated cisplatin response in urothelial carcinoma cells. **The 23rd Joint Annual Conference of Biomedical Sciences.**
23. Lai, Y. L., Kuan, C. I., **Hour, T. C.,** Pu, Y. S. and Huang, A. M. (2009) Characterization of CEBPD-mediated cisplatin response and resistance in urothelial carcinoma cells. **The 17th symposium on recent advances in cellular and molecular biology.**
24. Kao, Y. T., Toh S., Lin P. Y., **Hour, T. C.,** Pu, Y. S. and Huang, A. M. (2009) Proteomic approaches on CEBPD-mediated gemcitabine response in human urothelial carcinoma cells. **The 17th symposium on recent advances in cellular and molecular biology.**
25. Huang, A. M., Lai, Y. L., Kuan C. I., Pu, Y.S., and **Hour, T. C.** (2009) The molecular mechanism of CEBPD-mediated cisplatin response in urothelial carcinoma cells. **Genome Instability and DNA Repair (Keystone conference).**
26. Chung, S. J., **Hour, T. C.,** Huang, A. M., Liu, G. Y., Huang, S. P., Whang, S. T. and Pu, Y. S. (2009) Molecular characterization of human docetaxel-resistant prostate cancer cells. **The 14th Taiwan Joint Cancer Conference.**
27. Liu, F. T., **Hour, T. C.,** Kang, W. Y., Yu, H. J., Huang, C. Y., Pan, B. W., Wu, W. J., Huang, C. H. and Pu, Y. S. (2009) Chemokine CXCL14 (BRAK) expression and potential role in human renal cell carcinoma. **The 14th Taiwan Joint Cancer Conference.**
28. Huang, A. M., Lai,Y. L., Kuan, C. K., Sterneck, E., Wu, W. J., Pu, Y. S. and Hour, T. C. (2010) CEBPD induces SOD1 and cisplatin resistance in urothelial carcinoma. **Proceedings of the 101th American Association for Cancer Research**, **p1613**.
29. Huang, A. M., Tu, H. Y., Kuo, C. C., Hung, C. H., **Hour, T. C.,** Yang, S. C. and Lin, C. N. C4FAN13 exhibits cytotoxicity through G2/M arrest and induction of apoptosis in urinary system cancer. **Hormonal Oncogenesis**